References
- Sirois JG. Acute myocardial infarction. Emerg Med Clin North Am 1995; 13(4):759–69
- Kahn JK, Cragg DR, Almany SL, et al. Aggressive treatment of acute myocardial infarction. Postgrad Med 1993; 94(8):51–67
- Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1(8478):397–402
- Cooper JP, Quarry DP, Beale DJ, et al. Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J 1994; 70(826):592–3
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2(8607):349–60
- ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339(8796):753–70
- Kennedy JW, Ritchie JL, Davis KB, et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309(24): 1477–82
- Benedict CR, Mueller S, Anderson HV, et al. Thrombolytic therapy: a state of the art review. Hosp Pract 1992; 27(6):61–72